Vivos Therapeutics, Inc. (VVOS): Insider Trading, Congress Trades & Research | Tormere

VVOS

$0.11+1.27%visit website

Vivos Therapeutics, Inc.

Market Cap

$2M

Live price × SEC shares (Aug 13, 2026)

Sector

Health Care

Industry

Health Care

Beta (raw)

6.38

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

0.1

TTM to Jun 2026 · revenue

P/B

N/M

TTM to Jun 2026 · negative equity

EV/EBITDA (TTM)

N/M

TTM to Jun 2026 · negative EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	6,783	3,824	5,141	5,153	20,901
Gross profit	3,937	2,988	3,059	2,953	12,937
Total operating expenses	8,671	9,370	9,674	7,778	35,493
Operating income	(4,734)	(6,382)	(6,615)	(4,825)	(22,556)
Interest expense	500	800	1,100	1,100	3,500
Pretax income	(5,400)	(6,954)	(7,751)	(5,523)	(25,628)
Net income	(5,400)	(6,894)	(7,682)	(5,481)	(25,457)
EPS (basic) ($)	(0.49)		(0.52)	(0.31)	—
EPS (diluted) ($)	(0.49)		(0.52)	(0.31)	—
Weighted avg. shares (basic)	10,964		14,634	17,682
Weighted avg. shares (diluted)	10,964		14,634	17,682

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 14, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 22 more quarters, back to Mar 2020, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

9 analysts

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-03-31	2026-04-02	Skaff Michael C	10% Owner	Purchase	1.35M	$1.34	$1.81M	1.35M	View

Recent News

Vivos Therapeutics (VVOS) Stock Price, Chart & Analysis

debelegger.nl · 2026-11-02

CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test

Yahoo · 2026-10-29

Ralph Elias Green receives 12,000 Vivos Therapeutics (VVOS) options with a $0.18 exercise price.

Stock Titan · 2026-10-27

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

Yahoo · 2026-10-21

Vivos Therapeutics confirms Nasdaq compliance with $2.5M stockholders’ equity after SOD transaction

TradingView · 2026-10-21

Most Active US Stocks on Oct. 20, 2026: Low-Priced Shares Lead Volume

ChartMill · 2026-10-20

SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test

Yahoo · 2026-10-20

BC-Most Active Stocks

Yahoo · 2026-10-20

Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Benzinga · 2026-10-20

Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel

Yahoo · 2026-10-19

Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M

Benzinga · 2026-10-19

12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga · 2026-10-19

Vivos to buy 50% stake in SOD Sciences’ pseudohypoxia test

Yahoo · 2026-10-16

Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test

Yahoo · 2026-10-15

Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M

Benzinga · 2026-10-15

Informational purposes only, not investment advice.